Engineered immune cells target stomach cancer in new trial
NCT ID NCT07179484
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This study tests a special immune cell therapy called CT041 CAR-T in 20 adults with advanced stomach or gastroesophageal junction cancer. The treatment is given after standard first-line therapy to see if it can delay cancer growth. Participants receive their own immune cells that have been modified to attack cancer cells, and researchers monitor safety and how long the cells stay in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BeijingGoBroadH
RECRUITINGBeijing, 100142, China
Contact
Conditions
Explore the condition pages connected to this study.